Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT00873093 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

148

Enrollment

NIH

Sponsor class

Conditions

B-cell Adult Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Lymphoblastic Lymphoma
T-cell Adult Acute Lymphoblastic Leukemia
T-cell Childhood Acute Lymphoblastic Leukemia

Interventions

DRUG: L-asparaginase
DRUG: doxorubicin hydrochloride
DRUG: therapeutic hydrocortisone
DRUG: vincristine sulfate
DRUG: cytarabine
DRUG: prednisone
DRUG: bortezomib
DRUG: pegaspargase
DRUG: methotrexate
DRUG: etoposide phosphate
DRUG: cyclophosphamide
BIOLOGICAL: filgrastim
DRUG: leucovorin calcium
OTHER: laboratory biomarker analysis
DRUG: High Dose MTX

Sponsor

National Cancer Institute (NCI)